C-C Chemokine Receptor Type 4 – Drugs In Development, 2021

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report C-C Chemokine Receptor Type 4 – Drugs In Development, 2021, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) – C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5 and 1 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Dermatology, Ear Nose Throat Disorders, Gastrointestinal, Immunology, Ophthalmology, Respiratory and Undisclosed which include indications Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Melanoma, Non-Hodgkin Lymphoma, Solid Tumor, Adenocarcinoma Of The Gastroesophageal Junction, Allergic Asthma, Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Cervical Cancer, Chronic Urticaria Or Hives, Colon Tumor, Eosinophilic Esophagitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Pancreatic Tumor, Renal Cell Carcinoma, Rhinosinusitis, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC) and Unspecified.

Furthermore, this report also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)

– The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects

– The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Affitech A/S

ChemoCentryx Inc

CohBar Inc

Eight Plus One Pharmaceutical Co Ltd

Lassogen Inc

RAPT Therapeutics Inc

Tizona Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development

Affitech A/S

ChemoCentryx Inc

CohBar Inc

Eight Plus One Pharmaceutical Co Ltd

Lassogen Inc

RAPT Therapeutics Inc

Tizona Therapeutics Inc

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles

AT-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BJY-809 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-5046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-6239 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAS-20X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPT-193 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones

Featured News & Press Releases

Jun 14, 2021: RAPT Therapeutics reports positive topline results from phase 1b trial of RPT193 monotherapy in atopic dermatitis

Jun 13, 2021: RAPT Therapeutics to report top line data from phase 1b trial of RPT193 in atopic dermatitis

Mar 22, 2021: Rapt Therapeutics completes enrollment in phase 1b trial of RPT193 in atopic dermatitis

Nov 16, 2020: RAPT Therapeutics reports positive initial data from ongoing phase 1/2 clinical trial of FLX475 in multiple cancer indications

Nov 15, 2020: RAPT Therapeutics to announce initial data from phase 1/2 clinical trial of FLX475 in multiple cancer indications

May 15, 2020: RAPT Therapeutics highlights early results for RPT193 at Society for Investigative Dermatology Meeting

Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193

Jul 08, 2019: RAPT Therapeutics announces the appointment of Emma Guttman-Yassky, M.D., Ph.D., a leading expert in the field of inflammatory skin diseases, to its scientific advisory board

May 13, 2019: FLX Bio highlights preclinical atopic dermatitis and asthma data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019

Nov 29, 2018: ChemoCentryx announces presentation on novel small molecule inhibitor CCX6239 at American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Conference

Nov 08, 2018: FLX Bio highlights phase 1 data for FLX475 at SITC 2018

Sep 27, 2018: FLX Bio announces first patient dosed with FLX475, a best-in-class CCR4 inhibitor for the treatment of multiple cancers

Apr 12, 2018: FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting

Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate

Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Affitech A/S, 2021

Pipeline by ChemoCentryx Inc, 2021

Pipeline by CohBar Inc, 2021

Pipeline by Eight Plus One Pharmaceutical Co Ltd, 2021

Pipeline by Lassogen Inc, 2021

Pipeline by RAPT Therapeutics Inc, 2021

Pipeline by Tizona Therapeutics Inc, 2021

Dormant Projects, 2021

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports